In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...